What does semaglutide do to hs-CRP?

Semaglutide reduces hs-CRP, primarily through visceral fat reduction but potentially also through direct anti-inflammatory effects of GLP-1 receptor activation. The magnitude of hs-CRP reduction in clinical practice is proportional to the amount of visceral fat lost, my own clinical observation is consistent with the literature: patients losing 15–20% of body weight on semaglutide frequently see hs-CRP reductions of 1.5–2.5 mg/L over six to nine months. In a patient who started at 3.4 mg/L (high-risk cardiovascular inflammation), reaching 1.1 mg/L through this mechanism represents a clinically significant shift in plaque vulnerability risk.

The mechanism: visceral adipose tissue is the primary source of IL-6 and TNF-alpha that drive hepatic CRP production. Reducing visceral fat reduces the primary signal. The early cardiovascular event curve separation in SELECT suggests an additional direct anti-inflammatory effect through GLP-1 receptor activation in vascular tissue that precedes the inflammatory benefits of fat loss, but this is still being characterized mechanistically. The practical implication: hs-CRP is one of the most useful biomarkers for tracking semaglutide's cardiovascular efficacy specifically, not just its metabolic effects. Check it before starting and at six months. (Ridker et al., NEJM, 2008)

Cardiologist's calibrated position, Promising (2) for hs-CRP reduction through the visceral fat mechanism. The direct anti-inflammatory vascular mechanism: Early (3), biologically plausible, not yet isolated in human trials.

What to do: Establish baseline hs-CRP before starting semaglutide. Recheck at six months. A hs-CRP reduction of 1.0 mg/L or more is confirmation that the drug is producing the anti-inflammatory cardiovascular effect you are targeting.

For the full picture, read The Drug That Surprised Cardiologists.